This is a working overview of As-needed dosing, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
== Drinks == Tea (Chinese: 茶 chá) plays an important role in Chinese dining culture. Baijiu and huangjiu are strong alcoholic beverages that are preferred by many people as well. Wine is not as popular as other drinks in China that are consumed while dining, although they are usually available in the menu.
== Suicide == Since 2013, the National Suicide Observatory has published data on suicide trends in France. Sociological and demographic factors influence the incidence and outcome of suicide across genders.
== Treatment == Multiple effective therapies are available for the treatment of DM. Standard treatment typically consists of a combination of glucocorticoids and steroid-sparing immunosuppressive agents, including methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, and cyclosporine. Intravenous immunoglobulin (IVIG) has demonstrated efficacy in DM. Although rituximab did not meet its primary endpoint in randomized clinical trials, it remains an important treatment option in clinical practice, particularly for refractory disease, often in combination with IVIG. Janus kinase (JAK) inhibitors, including tofacitinib, ruxolitinib, baricitinib, and brepocitinib, have shown efficacy in dermatomyositis. Additional strategies targeting the type I interferon pathway have also demonstrated benefit, including blockade of interferon-β with dazukibart. Brepocitinib (Lisraya) was approved for medical use in the United States in August 2026. Deep B-cell depletion with CD19 chimeric antigen receptor (CAR) T-cell therapy has shown preliminary evidence of inducing sustained, and potentially treatment-free, remission in DM. Similarly, plasma cell–targeted therapies, including CAR T-cell approaches and monoclonal antibodies, as well as inhibitors of the neonatal Fc receptor (FcRn), such as efgartigimod, have emerged as promising therapeutic strategies for DM. Antimalarial medications, such as hydroxychloroquine, have historically been used to manage the cutaneous manifestations of DM.
Sources: en.wikipedia.org
The berries of most species can be eaten raw or used in pies. Wintergreen is a common flavoring in American products ranging from chewing gum, mints, and candies to smokeless tobacco such as dipping tobacco (American "dip" snuff) and snus. It is a common flavoring for dental hygiene products such as mouthwash and toothpaste. It is often a component of root beer, which originated in the United States. Wintergreen oil is an ingredient in some vegetable-oil based lubricants used in firearm maintenance. These products, sold under the names Seal1 and Frog Lube, are proprietary blends of vegetable oils intended to clean, lubricate and preserve the metal surfaces of firearms. They have the advantages over petroleum-based products of being non-toxic and biodegradable. Artificial wintergreen oil, which is pure methyl salicylate, is used in microscopy because of its high refractive index. Natural wintergreen oil can be distinguished from artificial by gas chromatography (GC) and GC isotope ratio mass spectrometry analysis.
ago. A more correct treatment would require the use of delay differential equations. Latent period is the transition time between contagion event and disease manifestation. In cases of diseases with varying latent periods, the basic reproduction number can be calculated as the sum of the reproduction numbers for each transition time into the disease. An example of this is tuberculosis (TB). Blower and coauthors calculated from a simple model of TB the following reproduction number:
13 December – The 2025 New Zealand bravery awards are announced. 14 December: A large fire engulfs four hectares of gum trees and slash near a eucalyptus forest in Kerikeri. 20 firefighters, two helicopters and a digger are deployed. A large vegetation fire breaks out along State Highway 4 near Parikino in the Whanganui District. 400 Air New Zealand cabin crew affiliated with the E tū union call off a planned strike on 18 December after reaching an "in principle agreement" with their employer. 15 December: Armed police are deployed to guard several Jewish sites nationwide including Kadimah School in response to the 2025 Bondi Beach shooting, which occurred yesterday. Police recover the bodies of an Australian climber and a dual Canadian-New Zealand climber who went missing in Fiordland National Park over the weekend. A large vegetation fire breaks out near Waiinu Beach in South Taranaki, leading to the evacuation of local residents. 16 December: Justice Richard McIlraith of the Manukau District Court voids the results of the Papatoetoe subdivision of the Ōtara-Papatoetoe Local Board election during the 2025 Auckland Council election, citing significant electoral irregularities. The Otago Regional Council orders the Dunedin City Council to stop discharging wastewater into Surrey Street and the Caversham area by June 2027. The New Zealand Government reduces transport subsidies for elderly and disabled people from 75% to 65%. The New Zealand Government announces plans to create a new mega ministry called the Ministry for Cities, Environment, Regions and Transport (MCERT).
Types include astrocytes, oligodendrocytes, microglia, and Schwann cells. Glia limitans A thin layer of astrocytic endfeet beneath the pia mater that forms part of the barrier separating the brain parenchyma from the cerebrospinal fluid. Glial scar A dense accumulation of glial cells, particularly astrocytes, that forms after central nervous system injury. It helps contain damage but can also inhibit axonal regeneration. Glioblastoma A highly aggressive and malignant brain tumor arising from glial cells. It is the most common primary brain cancer in adults and often has a poor prognosis. Glucocorticoid A class of steroid hormones released by the adrenal cortex in response to stress. They influence metabolism and have significant effects on memory and the hippocampus. Glutamate The main excitatory neurotransmitter in the brain. It is essential for learning, memory, and synaptic plasticity, but excessive levels can cause excitotoxicity. Glutamatergic Describes neurons or synapses that use glutamate as a neurotransmitter. These are the majority of excitatory synapses in the brain. Glycine An inhibitory neurotransmitter found primarily in the spinal cord and brainstem. It acts via glycine receptors and contributes to motor control and reflexes. Golgi cell A type of inhibitory interneuron in the cerebellum that regulates input from mossy fibers to granule cells via GABA release. Golgi stain A silver staining method that randomly labels a small subset of neurons in their entirety, allowing detailed study of neuronal morphology.
Sources: en.wikipedia.org
Four periods define Pakistani architecture: pre-Islamic, Islamic, colonial, and post-colonial. The onset of the Indus civilisation around the mid-3rd millennium BCE heralded an urban culture, evidenced by surviving large structures. Notable pre-Islamic settlements include Mohenjo-daro, Harappa, and Kot Diji. The fusion of Buddhism and Greek influences birthed a distinctive Greco-Buddhist style from the 1st century CE, exemplified by the renowned Gandhara style. Notable Buddhist architectural remnants include the Takht-i-Bahi monastery in Khyber Pakhtunkhwa. The advent of Islam in present-day Pakistan marked the cessation of Buddhist architecture, ushering in Islamic architecture. The notable Indo-Islamic structure, the tomb of Shah Rukn-i-Alam in Multan, remains significant. During the Mughal era, Persian-Islamic design merged with Hindustani art, seen in Lahore's architectural gems like the Badshahi Mosque and the Lahore Fort with the iconic Alamgiri Gate. Lahore also boasts the vibrant Wazir Khan Mosque, and the lush Shalimar Gardens. In the British colonial period, Indo-European buildings emerged, blending European and Indian-Islamic styles. Post-colonial identity shines through modern landmarks like the Faisal Mosque, Minar-e-Pakistan, and Mazar-e-Quaid. British architectural influence persists in structures across Lahore, Peshawar, and Karachi.
Pharmacodynamics is defined as how the body reacts to the drugs. Pharmacodynamics theory often investigates the binding affinity of ligands to their receptors. Ligands can be agonists, partial agonists or antagonists at specific receptors in the body. Agonists bind to receptors and produce a biological response, a partial agonist produces a biological response lower than that of a full agonist, antagonists have affinity for a receptor but do not produce a biological response. The ability of a ligand to produce a biological response is termed efficacy, in a dose-response profile it is indicated as percentage on the y-axis, where 100% is the maximal efficacy (all receptors are occupied). Binding affinity is the ability of a ligand to form a ligand-receptor complex either through weak attractive forces (reversible) or covalent bond (irreversible), therefore efficacy is dependent on binding affinity. Potency of drug is the measure of its effectiveness, EC50 is the drug concentration of a drug that produces an efficacy of 50% and the lower the concentration the higher the potency of the drug therefore EC50 can be used to compare potencies of drugs. Medication is said to have a narrow or wide therapeutic index, certain safety factor, or therapeutic window. This describes the ratio of desired effect to toxic effect. A compound with a narrow therapeutic index (close to one) exerts its desired effect at a dose close to its toxic dose. A compound with a wide therapeutic index (greater than five) exerts its desired effect at a dose substantially below its toxic dose.
While the +4 and the −3 positions in the Kozak sequence have the greatest relative importance in the establishing a favorable initiation context a CC or AA motif at −2 and −1 were found to be important in the initiation of translation in tobacco and maize plants. Protein synthesis in yeast was found to be highly affected by composition of the Kozak sequence in yeast, with adenine enrichment resulting in higher levels of gene expression. A suboptimal Kozak sequence can allow for the pre-initiation complex (PIC) to scan past the first AUG site and start initiation at a downstream AUG codon.
== Medical uses == Amitriptyline/chlordiazepoxide is used for the treatment of moderate to severe depression associated with moderate to severe anxiety. It has shown to be more effective in treating symptoms of anxiety, irritability, and hostility in patients with comorbid depression and anxiety than amitriptyline alone. It also has a quicker onset time than either amitriptyline or chlordiazepoxide on their own.
== Pharmacology == Since pembrolizumab is cleared from the circulation through non-specific catabolism, no metabolic drug interactions are expected and no studies were done on routes of elimination. The systemic clearance [rate] is about 0.2 L/day and the terminal half-life is about 25 days.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.